Medscape

Biomarkers May Predict Omalizumab Response in Urticaria

In patients with chronic spontaneous urticaria, biomarkers such as a positive chronic urticaria index and low blood histamine ...

Celltrion announces U.S. FDA approval of 300mg strength of OMLYCLO® (omalizumab-igec), the first and only FDA-approved interchangeable biosimilar to XOLAIR®

Celltrion, Inc. today announced the U.S. Food and Drug Administration (FDA) has approved a new presentation of OMLYCLO® (omalizumab-igec), the first and only biosimilar designated as interchangeable ...

Rethinking long-term allergy treatments: Experimental vaccine protects against anaphylaxis in mice

Researchers led by the Institut Pasteur, Université Paris, have developed a vaccine that elicits anti-Immunoglobulin E ...
Investing

FDA approves new dosing option for Celltrion’s omalizumab biosimilar

INCHEON, South Korea - Celltrion, Inc. announced Monday that the U.S. Food and Drug Administration (FDA) has approved a new 300mg/2mL presentation of OMLYCO (omalizumab-igec), expanding dosing options ...
European Medical Journal

Dupilumab Improves Quality of Life in Chronic Urticaria

Dupilumab enhances quality of life in chronic urticaria patients unresponsive to antihistamines. Find out how treatment can ...
Nature

Experimental vaccine prevents deadly allergic reactions in mice

An experimental vaccine protects genetically modified mice against severe allergic reactions for up to a year, according to ...
조선일보

Celltrion launches Omlyclo omalizumab biosimilar in major European markets

Celltrion said on the 25th that Omlyclo (OMLYCLO), a treatment for chronic spontaneous urticaria launched in Europe in Sep., has been released in major countries, including Germany, Spain, the United ...
New Scientist on MSN

Experimental vaccine prevents dangerous allergic attack for a year

By blocking a molecule that pushes the immune system into overdrive, a vaccine protects mice from life-threatening ...